(Total Views: 482)
Posted On: 09/25/2024 1:35:34 AM
Post# of 154302
It's a white women study ----
*A total of 247 patients were included in the study...
*The mean age of the patients was 53.6±12.5 years; 58% were women, 94% were white, 42% had type 2 diabetes, and 76% had moderate or advanced fibrosis.
*In patients taking lanifibranor, a drop in hemoglobin levels was observed.
*The investigators concluded, “In this phase 2b trial of patients with active NASH, the percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher with the 1200-mg once-daily dose of lanifibranor than with placebo. These findings support further assessment of lanifibranor in phase 3 trials.”
https://fattyliver.ca/blog/f/lanifibranor-may...-with-nash
Like you, no way medical mind, but no mention of reversal, etc...
Also Lanifibranor is 1200-mg once-daily dose.
_____
Cytodyn 1st MASH news:
SMC will be conducting a twelve-week preclinical mouse study evaluating both 350 and 700 mg dose levels
Yesterday:
Leronlimab monotherapy (700 mg) demonstrated statistically significant fibrosis reversal compared to an isotype IgG4 control arm (p<0.01)
Even the dosing is a huge disparity.
Then of course LL's safety will always be any tie-breaker, if needed.
Thanks for the info --- love looking @ even possible other players!
*A total of 247 patients were included in the study...
*The mean age of the patients was 53.6±12.5 years; 58% were women, 94% were white, 42% had type 2 diabetes, and 76% had moderate or advanced fibrosis.
*In patients taking lanifibranor, a drop in hemoglobin levels was observed.
*The investigators concluded, “In this phase 2b trial of patients with active NASH, the percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher with the 1200-mg once-daily dose of lanifibranor than with placebo. These findings support further assessment of lanifibranor in phase 3 trials.”
https://fattyliver.ca/blog/f/lanifibranor-may...-with-nash
Like you, no way medical mind, but no mention of reversal, etc...
Also Lanifibranor is 1200-mg once-daily dose.
_____
Cytodyn 1st MASH news:
SMC will be conducting a twelve-week preclinical mouse study evaluating both 350 and 700 mg dose levels
Yesterday:
Leronlimab monotherapy (700 mg) demonstrated statistically significant fibrosis reversal compared to an isotype IgG4 control arm (p<0.01)
Even the dosing is a huge disparity.
Then of course LL's safety will always be any tie-breaker, if needed.
Thanks for the info --- love looking @ even possible other players!
(2)
(0)
